Elevating the Vision for BPH Treatment

Durability + Patient Experience​

The UroLift™ System is a market leader and proven minimally invasive treatment for benign prostatic hyperplasia (BPH) that provides an alternative to BPH medications and major surgery.1,2  It is supported by over a decade of clinical evidence.

Read Latest Published Study

A proven earlier treatment alternative to BPH medications2

The only leading BPH minimally invasive surgical therapy (MIST) with consistent durability in the real-world and clinical trials2,3​

A safe, effective treatment,2 providing a superior patient experience* among leading BPH procedures3-5​

One of the most studied BPH MIST procedures with 145+ peer reviewed and clinical publications​

A Proven Earlier Treatment Alternative to Medications2

98%

of men seeing a doctor for BPH are treated with medications or watchful waiting1

Medications like alpha blockers, 5-ARIs or combination therapy are first-line treatment for patients with BPH symptoms, but they come with some significant tradeoffs.​

  • Maximum median IPSS score reduction for common BPH medications is only 7 points at 4 years6

  • Lifelong treatment and side effects7-16
  • Low compliance17
  • Long-term impact on bladder health18

Despite technological innovation, only 2% of men seeing a doctor for BPH are treated with a surgical intervention1​

Traditional invasive surgery like TURP has been the gold standard BPH treatment since the 1920's. Newer technology has been introduced over the years to help improve patient experience factors such as long-term recovery, post-op complications and ejaculatory dysfunction.

UroLift™ System

Market leading minimally invasive BPH procedure1

Grade 3+ or Serious Adverse Events​:

0.7%2

—

Sexual Function:

0% EjD**2

TURP

Traditional invasive surgery since 1926

Grade 3+ or Serious Adverse Events​:

7.6%19-20

–

Sexual Function:

36% EjD**19-20

Aquablation

Robotic waterjet ablation comparable to traditional invasive surgeries

Grade 3+ or Serious Adverse Events​:

6.9%19-20

— 

Sexual Function:

10% EjD**19-20

The graphic is for educational purposes only. Direct comparisons of studies cannot be made.

**De novo ED or EjDamong sexually active men

1 in 20​

Did you know? New data shows that within one year of BPH surgery, 1 in 20 patients may require retreatment regardless of the procedure type.3​

View the Study
Real-World Durability Analysis
Note: This webinar counts toward continuing education requirements for the UroLift™ System Center of Excellence program. To receive credit for watching the webinar, please view in UroLift University.

The Only Leading BPH MIST With Consistent Durability in Real World and Clinical Trials2,3

In a recent real-world analysis, the ​UroLift™ System demonstrated a comparable 5-year retreatment rate to the rate shown in the L.I.F.T. RCT (11.6% and 13.6%).2,3
Across clinical trials and real-world studies, the UroLift™ System has demonstrated largely consistent IPSS outcomes.2,21
5-year surgical retreatment rate vs. L.I.F.T. RCT surgical retreatment rate2,3 ​

Provides Superior Patient Experience* Among Leading BPH Procedures3-5​

Rapid relief with a low risk profile22-23​

Lowest catheter rate of the leading BPH procedures2,23-27

Preservation of sexual function***2​

 

Patient Safety

Once procedure volume is factored in, the UroLift™ System has the lowest rates of mild, moderate, and severe complications on a per case basis from 2019-202228

The UroLift™ System had the lowest post-procedural complication rate at one year compared to other procedures.3

MAUDE Study: Patient Safety
Note: This webinar counts toward continuing education requirements for the UroLift™ System Center of Excellence program. To receive credit for watching the webinar, please view in UroLift University.
Learn More About the UroLift™ System Procedure and the Latest Data